Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKinsey
Moodys
Harvard Business School
McKesson
Boehringer Ingelheim

Last Updated: December 5, 2021

DrugPatentWatch Database Preview

Patent: 9,421,194

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 9,421,194
Title:Lung targeting dual drug delivery system
Abstract: The American Cancer Society estimated that in 2009, 1,479,350 new cancer cases would be diagnosed in the United States of which 219,440 would be lung and bronchus related. The standard treatments for NSCLC include surgery, chemotherapy, radiation, laser and photodynamic therapy, all with various success rates depending on the stage of the cancer. National Cancer Institute assesses, however, that results of standard treatment are generally poor with only a 15 percent 5-year survival rate for combined cancer stages. Challenges facing the current chemotherapy drugs include excessive toxicity to healthy tissues and limited ability to prevent metastases. A dual drug delivery system described herein selectively targets the lung to deliver anti-cancer drugs and inhibit the formation of metastases.
Inventor(s): Prud\'homme; Robert K. (Lawrenceville, NJ), Sinko; Patrick J. (Annandale, NJ), Stone; Howard A. (Princeton, NJ), Pinkerton; Nathalie M. (Ottawa Hills, OH), Shi; Lei (Shanghai, CN), Wan; Jiandi (Lawrenceville, NJ), Ibrahim; Sherif (Old Bridge, NJ), Gao; Dayuan (East Brunswick, NJ)
Assignee: Rutgers, The State University of New Jersey (New Brunswick, NJ) The Trustees of Princeton University (Princeton, NJ)
Application Number:13/080,371
Patent Claims:see list of patent claims

Details for Patent 9,421,194

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 1998-09-25 ⤷  Try it Free 2030-04-05
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 2017-02-10 ⤷  Try it Free 2030-04-05
Genentech, Inc. HERCEPTIN HYLECTA trastuzumab and hyaluronidase-oysk Injection 761106 2019-02-28 ⤷  Try it Free 2030-04-05
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Colorcon
Johnson and Johnson
McKinsey
Mallinckrodt
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.